JP2008539782A5 - - Google Patents

Download PDF

Info

Publication number
JP2008539782A5
JP2008539782A5 JP2008511868A JP2008511868A JP2008539782A5 JP 2008539782 A5 JP2008539782 A5 JP 2008539782A5 JP 2008511868 A JP2008511868 A JP 2008511868A JP 2008511868 A JP2008511868 A JP 2008511868A JP 2008539782 A5 JP2008539782 A5 JP 2008539782A5
Authority
JP
Japan
Prior art keywords
marker
cancer
prostate cancer
haplotype
allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008511868A
Other languages
English (en)
Japanese (ja)
Other versions
JP5227167B2 (ja
JP2008539782A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IS2006/000012 external-priority patent/WO2006123369A1/en
Publication of JP2008539782A publication Critical patent/JP2008539782A/ja
Publication of JP2008539782A5 publication Critical patent/JP2008539782A5/ja
Application granted granted Critical
Publication of JP5227167B2 publication Critical patent/JP5227167B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008511868A 2005-05-18 2006-05-18 Ｃｈｒ８ｑ２４．２１での変異体は癌のリスクを与える Expired - Fee Related JP5227167B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US68214705P 2005-05-18 2005-05-18
US60/682,147 2005-05-18
US79576806P 2006-04-28 2006-04-28
US60/795,768 2006-04-28
PCT/IS2006/000012 WO2006123369A1 (en) 2005-05-18 2006-05-18 Variants at chr8q24.21 confer risk of cancer

Publications (3)

Publication Number Publication Date
JP2008539782A JP2008539782A (ja) 2008-11-20
JP2008539782A5 true JP2008539782A5 (https=) 2009-07-30
JP5227167B2 JP5227167B2 (ja) 2013-07-03

Family

ID=36830953

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008511868A Expired - Fee Related JP5227167B2 (ja) 2005-05-18 2006-05-18 Ｃｈｒ８ｑ２４．２１での変異体は癌のリスクを与える

Country Status (10)

Country Link
US (1) US20090317799A1 (https=)
EP (1) EP1888772A1 (https=)
JP (1) JP5227167B2 (https=)
AU (1) AU2006248591B2 (https=)
BR (1) BRPI0610794A2 (https=)
CA (1) CA2608567A1 (https=)
IL (1) IL187449A (https=)
MX (1) MX2007014447A (https=)
NZ (1) NZ563913A (https=)
WO (1) WO2006123369A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2009DN05722A (https=) * 2007-02-07 2015-07-24 Decode Genetics Ehf
CA2688312A1 (en) * 2007-05-25 2008-12-04 Decode Genetics Ehf. Genetic variants on chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
US8697360B2 (en) 2007-11-30 2014-04-15 Decode Genetics Ehf. Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition
US20090226912A1 (en) * 2007-12-21 2009-09-10 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
WO2012031207A2 (en) 2010-09-03 2012-03-08 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
US9534256B2 (en) 2011-01-06 2017-01-03 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
WO2013065072A1 (en) * 2011-10-30 2013-05-10 Decode Genetics Ehf Risk variants of prostate cancer
KR101944927B1 (ko) 2016-03-24 2019-02-07 서울대학교산학협력단 전립선암과 관련된 단일염기다형성 및 이를 이용한 유전 위험도 점수의 개발
KR20250074712A (ko) 2023-11-15 2025-05-28 주식회사 바스젠바이오 전립선암 발병의 위험도를 예측하기 위한 조성물 및 이를 이용한 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
EP0131052B1 (en) 1983-01-10 1993-12-08 Gen-Probe Incorporated Method for detecting, identifying, and quantitating organisms and viruses
US5288611A (en) 1983-01-10 1994-02-22 Gen-Probe Incorporated Method for detecting, identifying, and quantitating organisms and viruses
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
DE69132531T2 (de) 1990-12-06 2001-09-13 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verbindungen und ihre Verwendung in einer binären Synthesestrategie
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
ATE198358T1 (de) 1992-04-27 2001-01-15 Dartmouth College Detektion von gensequenzen in biologischen flüssigkeiten
DE69800415T2 (de) * 1997-12-22 2001-07-19 Genset, Paris Prostatakrebs-gen

Similar Documents

Publication Publication Date Title
Wang et al. Association analysis of IL-17A and IL-17F polymorphisms in Chinese Han women with breast cancer
TW200949249A (en) Methods, agents and kits for the detection of cancer
Hofer et al. Association of genetic variants of human telomerase with colorectal polyps and colorectal cancer risk
Ma et al. First evidence for the contribution of the genetic variations of BRCA1-interacting protein 1 (BRIP1) to the genetic susceptibility of cervical cancer
JP2008539782A5 (https=)
KR101582723B1 (ko) 대장암 발병 위험도 예측을 위한 유전 마커와 이의 이용
Mishra et al. Vascular endothelial growth factor single‐nucleotide polymorphism in gall bladder cancer
Guo et al. Genetic variations in the PI3K/AKT pathway predict platinum-based neoadjuvant chemotherapeutic sensitivity in squamous cervical cancer
JP2012517242A5 (https=)
Zhang et al. Prostate cancer susceptibility loci identified in GATA2 and ZMIZ1 in Chinese population
Qi et al. No association of EGF 5'UTR variant A61G and hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection
KR101206596B1 (ko) 폐암 발병 위험성 및 폐암 생존 예후의 예측용 ｓｎｐ 및 그에 의한 폐암 발병 위험성 및 폐암 생존 예후를 예측하는 방법
Krawczyk et al. Macrophage stimulating protein variation enhances the risk of sporadic extrahepatic cholangiocarcinoma
KR102195593B1 (ko) Ddc의 다형성을 이용한 소세포폐암의 예후 진단 방법
CN107254546A (zh) 一种与乳腺癌新辅助化疗疗效相关的snp标志物及其应用
Jung et al. TNFα promoter polymorphism is a risk factor for susceptibility in hepatocellular carcinoma in Korean population
WO2008121825A3 (en) Epidermal growth factor (egf) expression and/or polymorphisms thereof for predicting the risk of developing cancer
RU2440415C1 (ru) Набор синтетических олигонуклеотидов для определения нуклеотидной последовательности кодирующей части гена brca1 и выявления мутаций, ассоциированных с наследственными формами рака молочной железы
JP6915804B2 (ja) イリノテカンの治療効果予測方法及びそのためのキット
KR101806025B1 (ko) 비소세포폐암 환자의 항암제 치료 반응성 및 예후 예측용 ｓｎｐ 마커 및 이의 용도
KR101819795B1 (ko) 대장암 발병 진단 및 예측용 유전 마커
TW201514309A (zh) 檢測ｐ／ｐ血型的方法及其檢測套組
Al-Husseini et al. Assess the contribution of ribosomal RNA processing 1B gene polymorphisms in breast cancer in Iraqi patients.
AU2017270496B2 (en) Determination of genetic predisposition to aggressive prostate cancer
Aboelroos et al. Association between estrogen receptor alpha and aryl hydrocarbon receptor gene polymorphisms in the prognosis of breast cancer in Egypt